Compare · LLY vs RCUS
LLY vs RCUS
Side-by-side comparison of Eli Lilly and Company (LLY) and Arcus Biosciences Inc. (RCUS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and RCUS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.03T, about 338.4x RCUS ($3.06B).
- Over the past year, LLY is up 42.6% and RCUS is up 180.5% - RCUS leads by 137.9 points.
- RCUS has been more active in the news (11 items in the past 4 weeks vs 10 for LLY).
- LLY has more recent analyst coverage (25 ratings vs 16 for RCUS).
- Company
- Eli Lilly and Company
- Arcus Biosciences Inc.
- Price
- $1098.76-1.20%
- $24.29+0.62%
- Market cap
- $1.03T
- $3.06B
- 1M return
- +7.60%
- +6.77%
- 1Y return
- +42.62%
- +180.48%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2018
- News (4w)
- 10
- 11
- Recent ratings
- 25
- 16
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Arcus Biosciences Inc.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company is also developing Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Latest LLY
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.15% to 2,995 units (SEC Form 4)
- Director Luciano Juan R was granted 14 shares, increasing direct ownership by 0.08% to 16,891 units (SEC Form 4)
- Director Fyrwald J Erik was granted 9 shares, increasing direct ownership by 0.01% to 75,401 units (SEC Form 4)
- Director Alvarez Ralph was granted 11 shares, increasing direct ownership by 0.02% to 55,723 units (SEC Form 4)
- Zepbound (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable
- FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
- Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
- Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
- Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
- Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode
Latest RCUS
- Director Lambert Nicole was granted 5,700 shares, increasing direct ownership by 15% to 43,000 units (SEC Form 4)
- Director Kaneko Yasunori was granted 5,700 shares, increasing direct ownership by 28% to 25,700 units (SEC Form 4)
- Director Machado Patrick was granted 5,700 shares, increasing direct ownership by 15% to 44,300 units (SEC Form 4)
- General Counsel Tang Carolyn C. exercised 34,090 shares at a strike of $2.57, increasing direct ownership by 23% to 184,607 units (SEC Form 4)
- Director Lacey David L. was granted 5,700 shares, increasing direct ownership by 8% to 76,652 units (SEC Form 4)
- Director Ribas Antoni was granted 5,700 shares, increasing direct ownership by 15% to 44,300 units (SEC Form 4)
- Director Perlman Andrew J was granted 5,700 shares, increasing direct ownership by 13% to 48,325 units (SEC Form 4)
- Director Falberg Kathryn E was granted 5,700 shares, increasing direct ownership by 15% to 44,300 units (SEC Form 4)
- Arcus Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Arcus Biosciences Announces New Employment Inducement Grants